Shimauchi Tsukasa, Boucherat Olivier, Yokokawa Tetsuro, Grobs Yann, Wu WenHui, Orcholski Mark, Martineau Sandra, Omura Junichi, Tremblay Eve, Shimauchi Kana, Nadeau Valérie, Breuils-Bonnet Sandra, Paulin Roxane, Potus François, Provencher Steeve, Bonnet Sébastien
Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Québec, Canada.
Department of Medicine, Université Laval, Québec, Québec, Canada.
JACC Basic Transl Sci. 2022 Mar 16;7(4):384-403. doi: 10.1016/j.jacbts.2022.01.005. eCollection 2022 Apr.
The authors show that increased poly(adenosine diphosphate-ribose) polymerase 1 (PARP1) and pyruvate kinase muscle isozyme 2 (PKM2) expression is a common feature of a decompensated right ventricle in patients with pulmonary arterial hypertension and animal models. The authors find in vitro that overactivated PARP1 promotes cardiomyocyte dysfunction by favoring PKM2 expression and nuclear function, glycolytic gene expression, activation of nuclear factor κB-dependent proinflammatory factors. Pharmacologic and genetic inhibition of PARP1 or enforced tetramerization of PKM2 attenuates maladaptive remodeling improving right ventricular (RV) function in multiple rodent models. Taken together, these data implicate the PARP1/PKM2 axis as a critical driver of maladaptive RV remodeling and a new promising target to directly sustain RV function in patients with pulmonary arterial hypertension.
作者表明,多聚(二磷酸腺苷 - 核糖)聚合酶1(PARP1)和丙酮酸激酶肌肉同工酶2(PKM2)表达增加是肺动脉高压患者和动物模型中失代偿右心室的一个共同特征。作者在体外发现,过度激活的PARP1通过促进PKM2表达、核功能、糖酵解基因表达以及激活核因子κB依赖性促炎因子来促进心肌细胞功能障碍。在多个啮齿动物模型中,PARP1的药物和基因抑制或PKM2的强制四聚化可减轻适应性不良重塑,改善右心室(RV)功能。综上所述,这些数据表明PARP1/PKM2轴是适应性不良RV重塑的关键驱动因素,也是直接维持肺动脉高压患者RV功能的一个新的有前景的靶点。